17570-98-8

Usage

Uses

Used in Pharmaceutical Industry:
2-(Bromoacetyl)pyridine hydrobromide is used as a reagent for the synthesis of various pharmaceuticals and fine chemicals. Its unique structure allows for the creation of new compounds with potential therapeutic applications.
Used in Chemical Industry:
In the chemical industry, 2-(Bromoacetyl)pyridine hydrobromide serves as a key intermediate in the production of agrochemicals and specialty chemicals, contributing to the development of innovative products with specific applications.
Used in Chemical Research and Development:
2-(Bromoacetyl)pyridine hydrobromide is employed as a selective modifying agent for functional groups in organic molecules, facilitating targeted chemical reactions and the discovery of new chemical entities with potential applications in various fields.

InChI:InChI=1/C7H6BrNO.BrH/c8-5-7(10)6-3-1-2-4-9-6;/h1-4H,5H2;1H

Upstream product

• 1122-62-9 2-acetylpyridine 
• 113738-31-1 2-acetylpyridinium bromide 
• 1122-54-9 methyl (4-pyridyl) ketone 

Downstream Products

• 115933-97-6 2-pyridacyl benzoate 
• 408498-42-0 2-(pyridin-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 
• 121041-26-7 3-methoxy-6-(3'-methoxybenzylthio)-2-(pyridin-2''-yl)imidazo<1,2-b>pyridazine 
• 121040-71-9 3-methoxy-6-(2'-methoxyphenoxy)-2-(pyridin-2''-yl)imidazo<1,2-b>pyridazine 
• 1001013-86-0 2-(2-(4-iodophenyl)-1-(6-methylpyridin-3-yl)-1H-imidazol-4-yl)pyridine 
• 950185-64-5 [(2-Nitrophenyl)methyl](4-(2-pyridyl)(1,3-thiazol-2-yl))amine 
• 139420-56-7 2-Hydrazino-4-(2'-pyridyl)thiazole 
• 104484-16-4 3-[1-Phenyl-meth-(Z)-ylidene]-6-pyridin-2-yl-[1,4]oxathiin-2-one 
• 103441-80-1 2-oxo-2-(pyridin-2-yl)ethyl acetate 

Relevant academic research and scientific papers

Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53

We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc metallochaperones (ZMCs) that restore zinc binding by shuttling zinc into cells. We defined biophysical and cellular assays necessary for structure-activity relationship studies using this mechanism. We investigated an alternative class of zinc scaffolds that differ from TSCs by substitution of the thiocarbamoyl moiety with benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones. Members of this series bound zinc with similar affinity and functioned to reactivate mutant p53 comparable to the TSCs. Acute toxicity and efficacy assays in rodents demonstrated C1 to be significantly less toxic than the TSCs while demonstrating equivalent growth inhibition. We identified C85 as a ZMC with diminished copper binding that functions as a chemotherapy and radiation sensitizer. We conclude that the benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones can function as ZMCs to reactivate mutant p53 in vitro and in vivo.

Synthesis, antioxidant and antimicrobial properties of novel pyridyl-carbonyl thiazoles as dendrodoine analogs

Marine compound dendrodoine was first obtained from tunicate species (Dendrodo grossularia). It has a five-membered ring, namely, it is a heterocycle thiadiazole, which is found rarely in natural sources. Following its biological activities, novel analogs have been investigated recently. Synthesis of the analogs for this study is realized with uncommon thiazole closure, including methylene-carbonyl condensation. Structures are elucidated by NMR (1H, 13C) and HRMS spectrums. As an alkaloid derivative, antioxidant properties were evaluated with DPPH and FRAP assays and antimicrobial effect with microdilution method. Among the series, 3bc-3cf showed higher antioxidant activity than those having 3 or 4-pyridyl substituents. There is lesser activity for 2-pyridyl activity for 2-pyridyl containing group, which may be a result of intramolecular interactions. No activity was observed against gram-negative bacteria at 250 μg/mL. 3ae and 3ce showed activity at 64 μg/mL against S. aureus and 3ae showed activity at 16 μg/mL against S. epidermidis gram-positive bacteria. Chloramphenicol showed activity against all microorganisms at 8-16 μg/mL. Sixteen original dendrodoine analogs have been defined by close/higher activity compared to dendrodoine analogs and Trolox.

Two metal complex derivatives of pyridine thiazole ligand: synthesis, characterization and biological activity

In this work, two new metal(II) complexes with ligand based on pyridine thiazolone group, [Zn(L)2(TsO)2]2DMF (1), {[Cd(L)(NO3)2H2O)]DMF}n(2) (where L = 4-(pyridin-4-yl)-2-(2-(pyridin-2- ylm

SYNTHESIS AND CONFORMATIONAL ANALYSIS OF SOME OXISURAN METABOLITES AND THEIR O-METHYLDERIVATIVES

The synthesis is given of oxisuran (methylsulphinylmethyl-2-pyridyl ketone) and its metabolites and derivatives, whose structures are 2-Py-CO-CH2-SOxCH3 (X=0, 1, 2) and 2-Py-CHOR-CH2SOnCH3 (R=H, Me; n=0, 1, 2).From the results obtained in the reaction of oxisuran with different reducing agents, a new stereochemical pathway is suggested to explain the stereoselectivity observed in the reduction of β-ketosulphoxides with DIBAL.The conformational analysis of hydroxy and methoxyderivates is discussed in relation with that previously reported for 2-thioderivatives of phenylethanol and their O-methylderivates.The configurational assignment of diastereoisomeric sulphoxides is made on the basis of their different conformational behaviour, confirming the assigment deduced from the stereoselectivity observed in the reduction of oxisuran.

SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B rece

SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS

The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

AMORPHOUS SOLID FORM OF A BET PROTEIN INHIBITOR

The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.

Aminothiazole compound, and preparation method and application thereof

The invention discloses an aminothiazole compound, and a preparation method and an application thereof. The compound has a following structural formula. In the formula, n, m, x are all 0 or 1, and only one of the three is 1 or the three are 0 at a same time; R1 is hydrogen, 2-pyridyl, 3-pyridyl, 4-pyridyl, phenyl, 2-pyrazinyl, 2-furyl, 2-thienyl, 2-pyrrolyl, 2-quinolyl, or 2-methylenepyridine; R2 is hydrogen or alkane with 1-10 aliphatic carbon chains; R3 or R4 is hydrogen or as the picture; R5 is hydrogen, a structure as the picture, N,N-diethyl, N,N-dipropyl, methyl, ethyl, propyl, butyl, trifluoromethyl, methoxy or cyano; among R3, R4 and R5, two are hydrogen at a same time; R6 and R7 can be same or different, and can be H, alkane with 1-10 aliphatic carbon chains, olefin or alkyne. In animal bodies, the compounds can inhibit the proliferation and growth of KRAS high mutant tumors such as pancreatic cancer and colon cancer.

Synthesis and evaluation of the 2-aminothiazoles as anti-tubercular agents

The 2-aminothiazole series has anti-bacterial activity against the important global pathogen Mycobacterium tuberculosis. We explored the nature of the activity by designing and synthesizing a large number of analogs and testing these for activity against M. tuberculosis, as well as eukaryotic cells. We determined that the C-2 position of the thiazole can accommodate a range of lipophilic substitutions, while both the C-4 position and the thiazole core are sensitive to change. The series has good activity against M. tuberculosis growth with sub-micromolar minimum inhibitory concentrations being achieved. A representative analog was selective for mycobacterial species over other bacteria and was rapidly bactericidal against replicating M. tuberculosis. The mode of action does not appear to involve iron chelation. We conclude that this series has potential for further development as novel antitubercular agents.